Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As long the price close above 52.30 (200 DMA), we are in good shape. It's the stubborn 50 DMA that is keeping the price below 53.93.
Maple Leaf Green World Inc. Receives Conditional Listing Approval from Canadian Securities Exchange (CSE) and Appoints New VP of Marketing
2021-05-26 08:30:02 AM ET (GlobeNewswire)
Maple Leaf Green World Inc. ("Maple Leaf" or the "Company") (NEO: MGW, OTCQB: MGWFF) is pleased to announce that it has received conditional approval from the Canadian Securities Exchange (the "CSE") for the listing ("Listing") of the shares of the Company (the "Shares") subject to satisfying the listing requirements of the CSE.
Trading of the Company's shares is expected to commence on June 1, 2021 after filing of certain customary conditions required by the CSE. Upon completion of the final listing requirements, the Company's common shares will be delisted from the NEO Exchange.
The Company is also pleased to welcome Mr. Leonard Davis to lead its Sales & Marketing team as V.P. of Marketing. Mr. Davis played a pivotal role in orchestrating the Swissx cultivation partnership agreement as announced in the press release dated May 13, 2021.
Mr. Davis has been in the soft goods manufacturing and sourcing business for over thirty years, assisting various companies to streamline process, increase product quality and distribution. In January 2018, Mr. Davis co-founded AIP2020, a hemp based business in California, where he was COO and was responsible for manufacturing, development and marketing. Within the first 3 months, AIP2020 built a revenue stream of USD $100,000 per month selling flower and pre-rolls. After adding edibles, the revenue jumped to USD $150,000 within 2 months.
Mr. Davis's experiences led him to operate independently as a consultant where he shares his expertise in manufacturing, sourcing and development by constructing a framework that enables growth in both sales and profits. The Hemp industry is one of the fastest growing segments in the US and it is projected to reach USD $16B by 2027. Mr. Davis brings his passion, collaborative spirit and innovative mind set to a fast growing hemp industry.
"I had the pleasure of touring Maple Leaf's farm and discussing the operation with their management team. I was quite impressed with their setup and what they have achieved so far. They have a great product and I have some ideas that I believe can help elevate their presence in the market place. I feel comfortable with an initial annual revenue projection of USD $1-5M," says Leonard Davis.
"We are excited to have Mr. Davis join our sales and marketing team. His extensive experience in marketing and product development will expedite our sales goals and add great value to our management team. Welcome aboard!" said Raymond Lai, President & CEO of Maple Leaf.
For further information and updates regarding the Company, please visit https://www.mlgreenworld.com/.
For updates regarding the California CBG Hemp Project, please visit https://www.gsgreenworld.com/.
About Maple Leaf Green World Inc.
Maple Leaf is a public Canadian company that is focused on the hemp industry in North America. The Company currently has a hemp project in Southern California. With over 10 years of extensive greenhouse management experience, the Company applies its eco-agriculture knowledge and cultivation technology to produce contaminant-free cannabis products. Maple Leaf's long-term objective is to produce cannabis oil and to export its products to approved countries. The Company's common shares are listed for trading on the Aequitas NEO Exchange Inc. under the symbol "MGW" and on the OTCQB market under the symbol "MGWFF."
Nabriva Therapeutics Phase 3 Trial of Antibiotic Medication for Bacterial Pneumonia Meets Primary Endpoint
2021-05-26 07:11:52 AM ET (MT Newswires)
07:11 AM EDT, 05/26/2021 (MT Newswires) -- Nabriva Therapeutics AG (NBRV) said Tuesday that the phase 3 bridging study of lefamulin in Chinese adults with community acquired bacterial pneumonia has achieved its primary endpoint.
The topline results showed that lefamulin was non-inferior to moxifloxacin, with the former demonstrating a critical response success rate of 76.8% compared with 71.4% for moxifloxacin. Lefamulin, a pleuromutilin antibiotic, was also found to be generally safe and well-tolerated, with an overall rate of treatment-emergent adverse events comparable to that of moxifloxacin.
The biopharmaceutical company also said that research partner Sinovant Sciences signed a deal with Sumitomo Pharmaceuticals (Suzhou) Co. Ltd. for development and commercialization rights for lefamulin in Greater China. The deal is expected to close in calendar Q2.
Shares of Nabriva are up about 50% ahead of Wednesday's opening bell.
BRIEF-Sinovant Sciences And Nabriva Therapeutics Announce Positive Topline Results From Phase 3 Trial Of Lefamulin In Chinese Adults With Community Acquired Bacterial Pneumonia (Cabp)
2021-05-25 06:53:41 PM ET (Reuters)
May 25 (Reuters) - Nabriva Therapeutics PLC:
* SINOVANT SCIENCES AND NABRIVA THERAPEUTICS ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 TRIAL OF LEFAMULIN IN CHINESE ADULTS WITH COMMUNITY ACQUIRED BACTERIAL PNEUMONIA (CABP)
* NABRIVA THERAPEUTICS PLC - LEFAMULIN WAS GENERALLY SAFE AND WELL-TOLERATED IN CHINESE ADULTS
* NABRIVA THERAPEUTICS PLC - LEFAMULIN WAS SHOWN TO BE NON-INFERIOR TO MOXIFLOXACIN
* NABRIVA THERAPEUTICS PLC - GREATER CHINESE RIGHTS TO LEFAMULIN WILL BE HELD BY SUMITOMO PHARMACEUTICALS (SUZHOU) CO., LTD., Source text for Eikon: Further company coverage:
Market Chatter: Ford Motor to Unveil Two New EV Platforms at Capital Markets Day
2021-05-25 01:42:55 PM ET (MT Newswires)
01:42 PM EDT, 05/25/2021 (MT Newswires) -- Ford Motor Company (F) is set to unveil two all-electric vehicle platform plans at its Capital Markets Day on Wednesday, Reuters reported on Tuesday, citing sources familiar.
One of the platforms will be for full-size trucks and SUVs while another for cars and smaller SUVs, the report said. Ford said it does not comment on future product speculation, according to the report.
Earlier this year, Ford said it plans to invest at least $22 billion through 2025 to deliver all-electric vehicles.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
DraftKings Provides International Center for Responsible Gaming with Financial Support for First-of-its-kind Sports Wagering Research
2021-05-24 08:00:04 AM ET (GlobeNewswire)
DraftKings Inc. (Nasdaq: DKNG) today announced a financial commitment to the International Center for Responsible Gaming's (ICRG) Fund to Support Research on Sports Wagering (the Fund). As a result of DraftKings' contribution, the ICRG is able to proceed with a competitive request for applications from researchers around the world who are interested in pursuing groundbreaking research on problem gambling. The Fund specifically focuses on responsible gaming in sports betting, with the goal of developing peer-reviewed, scientifically based research that contributes meaningfully to the understanding and application of responsible gaming in the industry.
"The cornerstone of our commitment to customers is providing an enjoyable sports betting and gaming experience, and we recognize that we have a responsibility to ensure that customers are playing safely," said Jason Robins, DraftKings' co-founder, CEO and Chairman of the Board of Directors. "We are pleased to support the critical mission of the International Center for Responsible Gaming and fund important research that will drive responsible gaming innovation and customer safety forward for the entire industry."
A first-of-its-kind fund in the United States, the ICRG created the Fund to advance innovation and best practices for responsible sports betting. The Fund is accepting applications by researchers interested in exploring the below topics and others related to responsible sports betting:
-- Differences in sports wagering compared to other forms of gaming
-- Evaluation of efficacy of existing responsible gaming interventions and programs
-- Differences in prevalence and experience of problem gambling across demographics
"We are incredibly honored to have DraftKings' financial support, which was instrumental in satisfying our funding needs for the Fund to Support Research on Sports Wagering," said Dr. Russell Sanna, ICRG Executive Director. "With the expansion of sports betting across the United States, public health research will be critical in better understanding problem gaming, and we are deeply appreciative of the support from DraftKings to fund research that is cutting-edge and can be utilized across the industry and by consumers."
DraftKings' responsible gaming mission is to mitigate harm and protect vulnerable populations by providing game-changing technology, training, and resources for employees and consumers, and by supporting evidence-based research.
In addition to working collaboratively with leaders in responsible gaming like the ICRG, DraftKings tailors its products across fantasy sports, sports wagering, and iGaming to provide customers with industry-leading responsible gaming tools, resources, and services they need to play responsibly. These practices include limit setting, cooling-off periods, and self-exclusion from offerings. The company also uses its own channels, including email and social media, to regularly remind customers of responsible gaming behaviors. DraftKings is proud to be a Platinum Member of the National Council on Problem Gambling and a member of the American Gaming Association.
Researchers from top-tier academic institutions may compete for funding to discover new insights concerning public health and sports betting, with applications opening this summer and concluding September 2021. Grant applications will be peer-reviewed prior to the ICRG independent Scientific Advisory Board selecting the final recipient. The selected recipient will be announced in September 2021 and receive funds for a three-year project ending in 2024, with the potential for their research to be published earlier in the three-year period. The research fund is open to U.S.-based or international public, private, or non-profit organizations. To learn more about the Fund, please visit icrg.org/research-center/apply-icrg-funding.
To learn more about DraftKings' commitment to responsible gaming and to advancing social innovation around the world, please visit DraftKings SERVES.
About DraftKings
DraftKings Inc. is a digital sports entertainment and gaming company created to fuel the competitive spirit of sports fans with products that range across daily fantasy, regulated gaming and digital media. Headquartered in Boston, and launched in 2012 by Jason Robins, Matt Kalish and Paul Liberman, DraftKings is the only U.S.-based vertically integrated sports betting operator. DraftKings is a multi-channel provider of sports betting and gaming technologies, powering sports and gaming entertainment for 50+ operators in 17 countries. DraftKings' Sportsbook is live with mobile and/or retail betting operations in the United States pursuant to regulations in Colorado, Illinois, Indiana, Iowa, Michigan, Mississippi, New Hampshire, New Jersey, New York, Oregon, Pennsylvania, Tennessee, Virginia and West Virginia. DraftKings' daily fantasy sports product is available in 7 countries internationally with 15 distinct sports categories. DraftKings is the official daily fantasy partner of the NFL, MLB, NASCAR, PGA TOUR and UFC as well as an authorized gaming operator of the NBA and MLB, an official betting operator of the PGA TOUR and the official betting operator of UFC. DraftKings also owns Vegas Sports Information Network, Inc. (VSiN), a multi-platform broadcast and content company.
About ICRG
Since 1996, the International Center for Responsible Gaming, formerly the National Center for Responsible Gaming, a nonprofit agency, has successfully established a rigorous and thriving field of study designed to further our mission of helping individuals and families affected by gambling disorder through first-class research and evidence-based education programs.
DraftKings Joins NASCAR Star Bubba Wallace and 23XI Racing
2021-05-20 07:30:02 AM ET (GlobeNewswire)
Today, DraftKings Inc. (Nasdaq: DKNG) announced it will become the first Official Daily Fantasy Sports, iGaming and Sports Betting Partner of 23XI Racing and its esteemed driver, Bubba Wallace, pending regulatory approval in applicable jurisdictions. The official sponsorship will debut at the EchoPark Automotive Texas Grand Prix at Circuit of the Americas on Sunday May 23, 2021, with the team continuing to sport the DraftKings logo for each race of the 2021 season. While DraftKings is already the Official Daily Fantasy Partner of NASCAR, the agreement with 23XI Racing positions DraftKings to hit a new gear in its motorsports offerings, integrations and entertainment.
"Joining forces with the 23XI Racing organization near the beginning of its growth makes this collaboration all the more impactful for DraftKings," said Ezra Kucharz, Chief Business Officer at DraftKings. "Beyond the brand and product integrations of this deal, we also greatly admire Bubba Wallace's ongoing advocacy for social justice and Inclusion, Equity and Belonging efforts because they align perfectly with our company values."
The new deal allows DraftKings and 23XI Racing to promote an authentic in-app experience for racing fans, and they will also collaborate on a cross-channel social media content video series including race previews and data presented by DraftKings. Fans can also expect to see DraftKings as the primary partner of the No. 23 Camry at the NASCAR Cup Series Race at Pocono Raceway on Sunday, June 27, 2021. As the Official Free-to-Play Partner of 23XI Racing and Bubba Wallace, DraftKings Sportsbook will launch a free-to-play pool ahead of the event with custom prizes like signed Bubba Wallace merchandise.
"As we continue to build the foundation of 23XI Racing, it's important for us to add brands that align with our values both on and off the track," added interim 23XI Racing President Steve Lauletta. "DraftKings is a leader in sports technology and entertainment and a company that we were able to add to our already stellar list of sponsors who've joined us in our first year. Adding DraftKings allows us to bring unique experiences to our fans as we continue to grow our reach showcasing our team to fans outside the NASCAR platform, as well as work together in support for social justice and other Inclusion, Equality and Belonging efforts. We're looking forward to having DraftKings be a part of the growth of 23XI Racing and seeing them on the track at Pocono for their primary race."
"I'm excited to see what we are capable of creating together as we welcome DraftKings to the 23XI Racing family," said Bubba Wallace. "As a big fan of the company, this relationship marks a historic moment as we integrate with a leader in sports technology and entertainment to enhance the experience of racing fans across the board."
More information about DraftKings is available at www.draftkings.com. DraftKings' NASCAR and full line of products are available via iOS and Android here.
About DraftKings
DraftKings Inc. is a digital sports entertainment and gaming company created to fuel the competitive spirit of sports fans with products that range across daily fantasy, regulated gaming and digital media. Headquartered in Boston, and launched in 2012 by Jason Robins, Matt Kalish and Paul Liberman, DraftKings is the only U.S.-based vertically integrated sports betting operator. DraftKings is a multi-channel provider of sports betting and gaming technologies, powering sports and gaming entertainment for 50+ operators in 17 countries. DraftKings' Sportsbook is live with mobile and/or retail betting operations in the United States pursuant to regulations in Colorado, Illinois, Indiana, Iowa, Michigan, Mississippi, New Hampshire, New Jersey, New York, Oregon, Pennsylvania, Tennessee, Virginia and West Virginia. DraftKings' daily fantasy sports product is available in 7 countries internationally with 15 distinct sports categories. DraftKings is the official daily fantasy partner of the NFL, MLB, NASCAR, PGA TOUR and UFC as well as an authorized gaming operator of the NBA and MLB, an official betting operator of the PGA TOUR and the official betting operator of UFC. DraftKings also owns Vegas Sports Information Network, Inc. (VSiN), a multi-platform broadcast and content company.
About 23XI Racing
23XI Racing - pronounced twenty-three eleven - was founded by NBA legend Michael Jordan and three-time Daytona 500 winner Denny Hamlin in 2020. Rising NASCAR star Bubba Wallace is the single car team's driver. 23XI Racing's No. 23 Toyota Camry made its NASCAR Cup Series debut at the Daytona 500 on February 14, 2021 at Daytona International Speedway.
REDUCE-IT(R) Heart Failure Analyses by VASCEPA(R) (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology's 70th Annual Scientific Session
2021-05-15 08:00:00 AM ET (GlobeNewswire)
Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher achieved serum EPA levels
Amarin to Webcast Discussion of Data Presented at ACC.21 Monday, May 17, 2021 at 4:30 p.m., Eastern Time
Amarin Corporation plc (NASDAQ:AMRN) today announced the presentation of REDUCE-IT HEART FAILURE (HF) at ACC.21, the American College of Cardiology's 70th Annual Scientific Session, being held virtually from May 15 - 17, 2021. These new analyses supported by Amarin were presented on behalf of all authors by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
"The REDUCE-IT HF analyses provide interesting data about a potential new approach to addressing heart failure, a condition that continues to challenge patients and cardiologists worldwide," commented Dr. Deepak L. Bhatt, M.D., M.P.H., Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center, Professor of Medicine at Harvard Medical School, and principal investigator of REDUCE-IT. "The potential benefit of increased serum EPA levels in reducing the composite of cardiovascular death or new heart failure requiring hospitalization in at-risk patients is a novel finding for icosapent ethyl and requires further prospective validation. These results add to the growing body of knowledge regarding icosapent ethyl."
The REDUCE-IT HF analyses examined the effects of icosapent ethyl on the incidence of new heart failure by achieved on-treatment serum EPA levels in REDUCE-IT patients. New heart failure and new heart failure requiring hospitalization were prespecified tertiary endpoints and were not significant in the overall patient population. Post hoc analyses were conducted based on estimated average on-treatment EPA levels in patients in the icosapent ethyl group with available EPA measurements, as compared to patients in the placebo group with available EPA measurements; these analyses showed that new heart failure and new heart failure requiring hospitalization may be reduced in patients who achieve serum EPA levels higher than approximately 150 ug/mL, though this needs to be tested prospectively.
As previously reported, the REDUCE-IT cardiovascular outcomes study enrolled 8,179 patients who were required to be treated with statins and other conventional therapies, and all patients had controlled low-density lipoprotein cholesterol, elevated triglyceride levels, and either established cardiovascular disease or diabetes with other cardiovascular risk factors.
Heart failure is a major and often debilitating cardiovascular condition, significantly impacting not only patients and their loved ones, but also healthcare systems globally. In the United States (US), the latest statistical update from the American Heart Association (AHA) shows that approximately 6.0 million people have HF, with the prevalence projected to increase by 46% from 2012 to 2030, affecting >8 million people 18 years of age or older. The overall US cost of HF continues to rise as well; in 2012 the total cost for HF was estimated to be $30.7 billion, primarily attributable to direct medical costs. The trajectory we are on could lead to a 127% (or $69.8 billion) increase by 2030.
"Cardiovascular disease continues to be the leading cause of death worldwide, with the economic and societal burden increasing each year," said Steven Ketchum, Ph.D., senior vice president and president, research & development, and chief scientific officer, Amarin. "Heart failure, in particular, devastates patients, their families and economies with significant direct costs and societal impact. We owe it to at-risk patients to analyze the data from our cardiovascular outcomes study and explore whether therapies such as icosapent ethyl might ease the burden."
The REDUCE-IT HF analyses include both prespecified and post hoc analyses. Heart failure was a prespecified tertiary endpoint within REDUCE-IT. Approximately 14% of the patients did not have EPA levels determined at baseline; baseline characteristics and outcomes in those with or without EPA measures were similar. On-treatment EPA values were estimated from available annual serum samples.
Brigham and Women's Hospital receives research funding from Amarin for Dr. Bhatt's work as the REDUCE-IT study Chair.
The REDUCE-IT HF analyses can be found here. Additional REDUCE-IT and icosapent ethyl (EPA)-related topics will be presented at ACC.21 and can be found here.
Audio Webcast Information
Amarin will host an audio webcast on Monday, May 17, 2021, at 4:30 p.m. ET to further discuss these and other VASCEPA-related findings presented during ACC.21, with replay available for a period of 14 days. The discussion will include various clinicians and scientists and will be moderated by Amarin's chief medical officer, Craig Granowitz, M.D., Ph.D. To listen please register here, listen live on the investor relations section of the company's website at www.amarincorp.com, or via telephone by dialing 877-545-0320 within the United States, 973-528-0016 from outside the United States. A replay of the call will be made available for a period of two weeks following the conference call. To hear a replay of the call, dial 877-481-4010 within the United States, 919-882-2331, PIN: 41266. Any opinions or views expressed by the clinicians and scientists on the audio webcast are theirs alone. They have neither been scripted nor previewed by Amarin. While Amarin respects the scientific opinions of these clinicians and scientists, Amarin takes no responsibility for those opinions. Rather, this audio webcast is intended to provide summaries of recently presented scientific data for consideration by Amarin's investors.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
It will be a wild ride today. Buckle up and let’s see if the markets in general closes green at 4pm.
Keep an eye on the 44.79 level.
DraftKings sized up by Morgan Stanley after strong Q1 report
May 10, 2021 7:12 AM ETDraftKings Inc. (DKNG)
By: Clark Schultz, SA News Editor
Morgan Stanley adjusts estimates on DraftKings (NASDAQ:DKNG) after taking in the company's Q1 earnings report.
"Revenue significantly outperformed our expectations and 2021 revenue guidance was well ahead (again), but mgmt guided to greater EBITDA losses this year and will issue substantially more stock-based comp than we expected," updates analyst Thomas Allen.
The firm keeps an Overweight rating in place as it points to a forecast for strong market share over the longer term (~25% in sports betting and 18% in iGaming).
MS has a bull case price target on DraftKings of $182, a lowered base case PT of $63 and bear case PT of $11.
--Morgan Stanley Adjusts DraftKings' Price Target to $63 From $66, Maintains Overweight Rating
2021-05-10 09:06:18 AM ET (MT Newswires)
09:06 AM EDT, 05/10/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe.
--Needham Adjusts DraftKings' Price Target to $73 from $81, Keeps Buy Rating
2021-05-10 08:30:47 AM ET (MT Newswires)
08:30 AM EDT, 05/10/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe.
DraftKings Lifts 2021 Revenue Outlook as Online Gaming Gains, Return of Sports Drive First-Quarter Growth
2021-05-07 12:06:10 PM ET (MT Newswires)
12:06 PM EDT, 05/07/2021 (MT Newswires) -- DraftKings (DKNG), an online sports and casino games betting operator, booked a first-quarter revenue surge well above analyst estimates and raised its 2021 outlook Friday after more states legalized online gambling and the full slate of sporting events depleted by the COVID-19 pandemic last year returned.
The Boston-based company said it now expects fiscal 2021 full-year revenue of $1.05 billion to $1.15 billion, from prior guidance of $900 million to $1 billion. The Capital IQ consensus is for $1.05 billion. In the first quarter, revenue surged 253% to $312 million, outstripping analysts' $237 million average estimate.
"DraftKings is off to an outstanding start in 2021," said Chief Executive Jason Robins. "We continued to make progress and remain on track with the migration to our own in-house proprietary sports betting engine, strengthened our content and technology capabilities with the acquisitions of VSiN and BlueRibbon Software, and invested in further differentiating our product offering with the upcoming rollout of social functionality in our DFS and mobile Sportsbook apps."
Still, the company reported a net loss per share of $0.87 for the quarter ended March 31, widening from $0.37 a year earlier and missing the consensus for a $0.45 loss on a GAAP basis. In it earnings presentation, DiamondKings reported an adjusted loss of $0.36, with no year-ago comparison immediately available.
Monthly unique paid users increased 114% to more than 1.5 million and average revenue per user rose 48% to $61, aided by the rollout of mobile casino and sportsbook offerings in additional states.
DraftKings said it now offers online sports betting in 12 states with about 25% of US population after entering Michigan and Virginia during the quarter. Michigan also became one of four states to allow the company to offer online casino games.
"We believe the outlook for further legalization is very promising," Robins said on a conference call with analysts, according to a Capital IQ transcript.
DraftKings Reports First Quarter 2021 Results and Raises 2021 Revenue Guidance
2021-05-07 07:00:20 AM ET (GlobeNewswire)
DraftKings Inc. (Nasdaq: DKNG) ("DraftKings" or the "Company") today reported first quarter 2021 financial results.
First Quarter 2021 Highlights
For the three months ended March 31, 2021, DraftKings reported revenue of $312 million, an increase of 253% compared to $89 million during the same period in 2020. After giving pro forma effect to the business combination with SBTech (Global) Limited ("SBTech") and Diamond Eagle Acquisition Corp. which was completed on April 23, 2020, as if it had occurred on January 1, 2019, revenue grew 175% compared to the three months ended March 31, 2020.
"DraftKings is off to an outstanding start in 2021," said Jason Robins, DraftKings' co-founder, CEO and Chairman of the Board. "We continued to make progress and remain on track with the migration to our own in-house proprietary sports betting engine, strengthened our content and technology capabilities with the acquisitions of VSiN and BlueRibbon Software, and invested in further differentiating our product offering with the upcoming rollout of social functionality in our DFS and mobile Sportsbook apps."
Jason Park, DraftKings' Chief Financial Officer, added, "Our $312 million in first quarter revenue, 114% increase in MUPs and 48% growth in ARPMUP reflect solid customer acquisition and retention as well as successful launches of mobile sports betting and iGaming in new states. We are raising our revenue outlook for 2021 due to the outperformance of our core business in the first quarter and our expectation for continued healthy growth."
Strong Customer Retention and Acquisition Drove Q1 Results
-- Monthly Unique Payers ("MUPs") for our B2C segment increased 114% compared to the first quarter of 2020. On average, 1.5 million monthly unique paying customers engaged with DraftKings each month during the first quarter. The increase reflects strong unique payer retention and acquisition across Daily Fantasy Sports, Online Sports Betting and iGaming.
-- Average Revenue per MUP ("ARPMUP") was $61 in the first quarter representing a 48% increase versus the same period in 2020. Our ARPMUP was positively impacted by increased engagement with our iGaming and mobile sports betting product offerings as well as successful cross-selling.
Increasing 2021 Revenue Guidance
-- DraftKings is raising its fiscal year 2021 revenue guidance from a range of $900 million to $1 billion to a range of $1.05 billion to $1.15 billion, which equates to year-over-year growth of 63% to 79% and a 16% increase compared to the midpoint of our previous guidance.
-- The increase reflects solid performance in the first quarter of 2021, continued strong user activation due to the effectiveness of our marketing spend, well-executed launches of mobile sports betting and iGaming in Michigan and mobile sports betting in Virginia, and a modest contribution from our recently completed acquisitions. This guidance also assumes that all professional and college sports calendars that have been announced come to fruition and that we continue to operate in states in which we are live today.
-- Detailed financial data and other information is available in DraftKings' Quarterly Report on Form 10-Q, being filed today with the Securities and Exchange Commission (the "SEC"), as well as in a slide presentation that can be accessed through the "Investors" section of the Company's website at investors.draftkings.com.
DraftKings Grows Its Mobile Sports Betting and iGaming Footprint
-- In the first quarter of 2021, DraftKings launched mobile sports betting and iGaming in Michigan and mobile sports betting in Virginia.
-- DraftKings is live with online sports betting in 12 states that collectively represent 25% of the U.S. population. DraftKings is live with iGaming in 4 states, representing approximately 10% of the U.S. population.
-- In 2021, 25 state legislatures have introduced legislation to legalize mobile sports betting, 5 state legislatures have introduced legislation to expand their existing sports wagering frameworks and 1 state legislature has introduced legislation to legalize sports betting limited to retail locations. In addition, 4 states have introduced iGaming legislation and 3 states have introduced online poker legislation.
-- Three of the states that introduced legislation to legalize mobile sports betting this year - Wyoming, Arizona and New York - have already enacted mobile sports wagering laws. Maryland has made significant progress with a mobile and retail sports wagering bill passing the legislature and now pending action from the Governor. The three states that have enacted mobile sports wagering laws this year represent 8% of the U.S. population and bring the percentage of the population with legalized mobile sports betting to 35%.
Leadership and Board Updates
-- DraftKings announced the appointment of Gisele Bundchen, environmental activist and philanthropist, as a special advisor to the Company's Chief Executive Officer and board of directors for environmental, social, and governance ("ESG") initiatives.
-- We expanded our executive team with the addition of Brian Angiolet to oversee and optimize content creation and media strategy as the Company's first Chief Media Officer.
Environmental, Social and Governance Initiatives Continue to Grow
-- We undertook a variety of internal and external efforts in honor of International Women's Day to support women entrepreneurs and small business owners throughout March, while also recognizing the day as an official company holiday for our global employees. Customer participation in the Women's History Month Sports Popularity Pool, which highlighted the greatest athletes and moments in women's sports, helped generate $300,000 in total donations to several U.S. and global organizations focused on empowering and aiding women entrepreneurs and women-founded small businesses.
-- We raised $184,000 through charity DFS contests in support of Feeding Texas' efforts to provide help to those impacted by the winter storms in Texas.
Product Developments, Content Initiatives and Commercial Agreements
-- The migration to our proprietary in-house back end and trading technology continues to be on-track for completion by the end of the third quarter of 2021.
-- We are announcing the upcoming rollout of social functionality to our DFS and mobile Sportsbook apps, marking an industry-first innovation to create an integrated social community across sports betting and daily fantasy sports, as fans can interact with each other within a shared, peer-to-peer environment. The product is particularly unique because it amplifies our ability to create an interconnected ecosystem across our consumer products. Features like universal profiles, friends lists, commenting and loyalty/rewards will allow DraftKings to connect users across products.
-- We acquired Vegas Sports Information Network, Inc. (VSiN), a multi-platform broadcast and content company delivering trusted sports betting news, analysis and data to U.S. sports bettors since 2017.
-- We acquired BlueRibbon Software Ltd., a leading global jackpot and gamification company that provides platform-agnostic, real-time gamification tools that allow for fully customizable jackpot promotions.
-- We announced an agreement with DISH Network to bring DraftKings' sportsbook and daily fantasy experiences directly to DISH customers nationwide, beginning with a first-of-its-kind and patent-pending DraftKings app integration on the DISH TV Hopper platform. The agreement also provided for the subsequent launch of SLING TV's new exclusive sports betting information channels in collaboration with DraftKings. SLING TV subscribers and SLING Free users can now view real-time game scores and betting odds on the DraftKings Basketball, Baseball and Hockey channels. SLING TV will continue to bring the DraftKings sports betting experience to customers with more sports and expanded offerings in the future.
-- DraftKings became UFC's first-ever "Official Sportsbook and Daily Fantasy Partner" in the United States and Canada and will now be able to offer in-game promotions, activations, in-broadcast odds integrations and UFC branding across its daily fantasy and betting products and will possess rights to use official UFC marks and logos.
Webcast and Conference Call Details
DraftKings will host a conference call and audio webcast today at 8:30 a.m. EDT, during which management will discuss the Company's first quarter results and provide commentary on business performance. A question and answer session will follow the prepared remarks.
The conference call may be accessed by dialing (833) 644-0686 for domestic callers or (918) 922-6762 for international callers. Once connected with the operator, please provide the conference ID of 8667046.
A live audio webcast of the earnings conference call may be accessed on the Company's website at investors.draftkings.com, along with a copy of this press release, the Company's Form 10-Q filing, and a slide presentation. The audio webcast and accompanying presentation will be available on the Company's investor relations website until 11:59 p.m. EDT on June 14, 2021.
About DraftKings
DraftKings Inc. is a digital sports entertainment and gaming company created to fuel the competitive spirit of sports fans with products that range across daily fantasy, regulated gaming and digital media. Headquartered in Boston, and launched in 2012 by Jason Robins, Matt Kalish and Paul Liberman, DraftKings is the only U.S.-based vertically integrated sports betting operator. DraftKings is a multi-channel provider of sports betting and gaming technologies, powering sports and gaming entertainment for 50+ operators in 17 countries. DraftKings' Sportsbook is live with mobile and/or retail betting operations in the United States pursuant to regulations in Colorado, Illinois, Indiana, Iowa, Michigan, Mississippi, New Hampshire, New Jersey, New York, Oregon, Pennsylvania, Tennessee, Virginia and West Virginia. DraftKings' daily fantasy sports product is available in 7 countries internationally with 15 distinct sports categories. DraftKings is the official daily fantasy partner of the NFL, MLB, NASCAR, PGA TOUR and UFC as well as an authorized gaming operator of the NBA and MLB, an official betting operator of the PGA TOUR and the official betting operator of UFC. DraftKings also owns Vegas Sports Information Network, Inc. (VSiN), a multi-platform broadcast and content company.
I couldn’t resist and bought more on today’s price dip. The 200 day moving average is 51.01 and the Nasdaq is back in the green. Tech is oversold.
Maple Leaf Green World Inc. debuts Phoenix Crave with Hempacco at TPE - Tobacco Plus Expo
2021-05-06 08:54:07 AM ET (GlobeNewswire)
Maple Leaf Green World Inc. ("Maple Leaf" or the "Company") (NEO: MGW, OTCQB: MGWFF) is pleased to announce it will debut their CBG Hemp Cigarettes at the TPE - Tobacco Plus Expo this upcoming May 12-14 at booth 10106.
Maple Leaf, tasking their new brand manager and joint venture partner Hempacco, has created the first in a new line of hemp cigarettes that will include CBG, CBD, and other functional smokes that will make their debut at the TPE - Tobacco Plus Expo this upcoming May 12-14 at booth 10106.
"After analyzing market trends in the hemp smokable world, we decided to start our line of hemp smokables with a natural flavor or a hemp flavor," said Raymond Lai, CEO of Maple Leaf Green World Inc. "We agreed with Hempacco to go after early adaptors of hemp smokables and crossover smokers from cannabis into hemp and CBG for those looking for a focusing experience, such as the one CBG gives you. With the upcoming TPE show we have the perfect opportunity to launch our product into the marketplace because wholesale distributors and retail buyers attend the show looking for products," said Lai.
Maple Leaf will manufacture their all-natural hemp cigarettes using CBG from their CBG farm located in Riverside, California, minutes away from the hemp cigarette manufacturing facility. The Company entered the pre-manufacturing phase of brand management with partner Hempacco; after the artwork was completed, the box was designed, and all the branding and fabrication elements were ordered.
"I've been spending a great deal of time in San Diego, California to work side-by-side with founders Sandro Piancone and Jorge Olson as well as the entire team at Hempacco," said Billy Bewcyk, VP of Business Development for Maple Leaf. "The entire project has been eye-opening for me, and the progress we've made in this short time has been amazing. We're ready to go into production this week, and we'll be ready to go into distribution next week at the TPE expo," concluded Bewcyk.
After producing a natural flavor in a 20-pack of CBG hemp cigarettes, Maple Leaf plans on joining Hempacco in Disrupting Tobacco(TM), for this, Maple Leaf will use Hempacco's intellectual property to flavor hemp cigarettes, starting by producing a mint-flavored line of hemp cigarettes.
"It's been a pleasure to have Billy Bewcyk of Maple Leaf work with us in developing Phoenix Crave CBG Hemp Cigarettes. The product looks sensational, and we work great together, so much so that I can't wait to hit the TPE trade show next week and together start selling Phoenix Crave hemp cigarettes to distributors," said Sandro Piancone, CEO of Hempacco.
All Company products, including the CBG farm in California, are currently available for viewing on their website at www.gsgreenworld.com and for sale by contacting sales@gsgreenworld.com. All products will be made available for online ordering after the official launch of the e-commerce platform that is currently in development.
For further information and updates regarding the Company, please visit https://www.mlgreenworld.com/.
For updates regarding the California CBG Hemp Project, please visit https://www.gsgreenworld.com/.
About Maple Leaf Green World Inc.
Maple Leaf is a public Canadian company that is focused on the hemp industry in North America. The Company currently has a hemp project in Southern California. With over 10 years of extensive greenhouse management experience, the Company applies its eco-agriculture knowledge and cultivation technology to produce contaminant-free cannabis products. Maple Leaf's long-term objective is to produce cannabis oil and to export its products to approved countries. The Company's common shares are listed for trading on the Aequitas NEO Exchange Inc. under the symbol "MGW" and on the OTCQB market under the symbol "MGWFF."
About Hempacco, Co. Inc.
Hempacco is Disrupting Tobacco's(TM) nearly $1 Trillion industry with herb and hemp-based alternatives to cigarettes by manufacturing and marketing consumer goods.
The company owns research and development, manufacturing and sales of smokable hemp brands, including The Real Stuff(TM) Hemp Smokables.
Hempacco's profit centers include private label agreements, Intellectual Property licensing, and the development and sales of their brands using patented counter displays as well as six hundred Kiosk vending machines called HempBoxes(TM). Learn more about Hempacco's Hemp Cigarettes: https://www.hempaccoinc.com
DraftKings Likely to Raise Full-Year Revenue Guidance Amid Strength in iGaming in Q1, BofA Says
2021-05-04 02:09:06 PM ET (MT Newswires)
02:09 PM EDT, 05/04/2021 (MT Newswires) -- DraftKings (DKNG) is expected to revise its full-year 2021 revenue guidance higher as Q1 sales are likely to come notably above the Street's estimates due primarily to the "strength" in the company's iGaming business, BofA Securities said in a research note Tuesday.
BofA analysts lifted the Q1 sales outlook to $296 million from their previous forecast of $242 million, compared to the market's expectations of $237 million. Q1 results, which are likely to show iGaming sales soared by 45% quarter on quarter, are due May 7.
The brokerage anticipates a revised sales guidance range from the firm of $1 billion to $1.1 billion, versus earlier projections of $900 million to $1 billion, "given the productivity" in new states.
"DKNG tends to be conservative so the raise may be more modest than the $1.2 billion run-rate implied by Q1," the analysts said. BofA has a $70 price target on the stock and a neutral rating, which was because of factors such as "steep" valuation and more cautious sentiment across the online gaming space.
DraftKings is not for the faint at heart. This one moves and it can get quite volatile in either direction. At the moment, this industry is just starting and it will explode very quickly. Patience is need with this one.
Good move on accumulating more on the pullbacks. I am overweighted now with DraftKings and won’t be buying more unless it goes below 50.00, despite cash is just sitting in my account.
The whole market in general is down. Earnings will be out this Friday.
--Cowen Upgrades DraftKings to Outperform From Market Perform; Price Target is $70
2021-05-03 07:30:05 AM ET (MT Newswires)
07:30 AM EDT, 05/03/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe.
--Guggenheim Initiates Coverage on DraftKings With Buy Rating, $75 Price Target
2021-04-30 07:37:21 AM ET (MT Newswires)
07:37 AM EDT, 04/30/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe.
DraftKings Strikes First Distribution and Content Relationship With Meadowlark Media
2021-04-27 12:30:00 PM ET (GlobeNewswire)
DraftKings Inc. (Nasdaq: DKNG) today continued to broaden its sports entertainment footprint by completing a first-of-its-kind content distribution, monetization and sponsorship agreement with Meadowlark Media. As part of the deal, Meadowlark Media and DraftKings will distribute The Dan Le Batard Show with Stugotz and the Le Batard & Friends Network across a wide range of audio, TV, digital and social channels. Additionally, the network of shows will prominently feature DraftKings' odds, betting trends and general sportsbook and daily fantasy information.
"We're thrilled to find a collaborator in DraftKings that shares our vision to grow Dan Le Batard's already wildly popular network of shows in non-conventional ways," said Meadowlark CEO John Skipper. "With the freedom to widely distribute these programs, we'll be able to reach the largest possible audience and provide incredible content to DraftKings."
Continuing its expansion into content and media after the acquisition of Vegas Sports and Information Network (VSiN), DraftKings plans to commission new content projects that Meadowlark will develop and produce. Additionally, DraftKings recently announced the hiring of Chief Media Officer, Brian Angiolet, to oversee and optimize content creation and media strategy, which includes working with VSiN and Meadowlark on efficient content models to maximize reach.
"John Skipper and Dan Le Batard have established a deep roster of content creators that will continue to expand quality and original programming," said Jason Robins, CEO, co-founder and chairman, DraftKings. "Our relationship with Meadowlark Media demonstrates DraftKings' dynamic approach in bringing premium content to skin-in-the-game sports fans through numerous channels."
The Dan Le Batard Show with Stugotz will continue to be available in podcast form with new formats of the show set to launch later this year. Since leaving ESPN Radio on January 4, the show has consistently ranked among the top sports programs on Apple podcasts.
"Thank you, DraftKings, for empowering us with the exhilarating combination of rocket fuel and total freedom," said Le Batard. "I'm overjoyed to team with a fearless creative partner who sees the future and wants to help us change it. DraftKings believed in us, our principles and our mission enough to give us a freedom no scared corporation or traditional media partner ever could or ever would. To our fans, know that DraftKings is the reason you aren't behind a paywall, and I'm promising you the money won't change the show or corrupt us in any way. Sincerely, Draft Le Batard."
Earnings in 10 actual days. The technical charts are priming for the next move up. I hope it doesn’t rise too much/too fast towards earnings release, as it may lead to overextended to the upside.
Needham Initiates DraftKings at Buy With $81 Price Target
2021-04-27 08:38:01 AM ET (MT Newswires)
08:38 AM EDT, 04/27/2021 (MT Newswires) -- DraftKings (DKNG) has an average outperform rating and a price target range of $41 to $105, according to analysts polled by Capital IQ.
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe.
Maple Leaf Green World Inc. Has Created Its Own Brand Name - Phoenix Crave
2021-04-22 08:30:11 AM ET (GlobeNewswire)
Maple Leaf Green World Inc. ("Maple Leaf" or the "Company") (NEO: MGW, OTCQB: MGWFF) is pleased to announce it has developed its own unique brand name, PHOENIX CRAVE, for its high quality CBG products. A preview of the Phoenix Crave artwork can be viewed on the Company's websites.
The Company is also pleased to announce the following new business developments:
New Distribution Networks
The Company has established a West Coast distribution network encompassing California, Oregon and Arizona. Two other distribution networks in Nevada and Florida are currently being set up. The Nevada agent is waiting on the results of a lab test to confirm there are no contaminants in the Company's products as required by the Nevada State laws before launching its marketing campaign.
New Products Development Update
CBG Hemp Cigarette
The Company has completed and approved the packaging artwork with its joint venture partner, Hempacco Co. Inc. ("Hempacco"). The artwork will now be sent through Hempacco's printing and packaging process to produce Phoenix Crave Gold and Phoenix Crave Gold Grape Flavor cigarette boxes. The initial batch will produce commercial ready sample packs to be sent to the Company's distribution networks, partners and dispensaries. The two retail ready, 20-packs of CBG Hemp Cigarettes will also debut through the Phoenix Crave e-commerce platform that is currently in development.
CBG Pre-Rolls
The Company has also been packaging its own CBG Hemp Pre-rolls for purchase through its own sales network. The CBG Hemp Pre-rolls offer a high-end product that is a great alternative to tobacco cigarettes. Each pre-roll contains 1 gram of premium CBG hemp and less than 0.2% THC. These pre-rolls can be purchased individually or in packs of 2.
CBG Oil
The Company has also shipped a test sample of biomass to a lab in California to produce CBG Crude. The Company is pleased with the results and are currently selecting a processing facility to further refine the crude to manufacture CBG Oil and CBG Gel Capsules.
All Company products are currently available for viewing on their website at www.gsgreenworld.com and for sale by contacting sales@gsgreenworld.com. All products will be made available for online ordering after the official launch of the e-commerce platform.
For further information and updates regarding the Company, please visit https://www.mlgreenworld.com/.
For updates regarding the California CBG Hemp Project, please visit https://www.gsgreenworld.com/.
About Maple Leaf Green World Inc.
Maple Leaf is a public Canadian company that focuses on the cannabis and hemp industry in North America. The Company currently has cannabis and hemp projects in British Columbia and California. With over 10 years of extensive greenhouse management experience, the Company applies its eco-agriculture knowledge and cultivation technology to produce contaminant-free cannabis products. Maple Leaf's long-term objective is to produce cannabis oil and to export its products to approved countries. The Company's common shares are listed for trading on the Aequitas NEO Exchange Inc. under the symbol "MGW" and on the OTCQB market under the symbol "MGWFF."
--Goldman Sachs Adjusts DraftKings' Price Target to $88 from $87, Keeps Buy Rating
2021-04-21 11:00:26 AM ET (MT Newswires)
11:00 AM EDT, 04/21/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe.
BRIEF-Gisele Bündchen Joins Draftkings As Special Advisor To The CEO And Board For ESG Initiatives
2021-04-21 07:37:33 AM ET (Reuters)
April 21 (Reuters) - Draftkings Inc:
* GISELE BÜNDCHEN JOINS DRAFTKINGS AS SPECIAL ADVISOR TO THE CEO AND BOARD FOR ESG INITIATIVES
* DRAFTKINGS INC - APPOINTMENT OF GISELE BÜNDCHEN AS A SPECIAL ADVISOR TO COMPANY'S CEO AND BOARD OF DIRECTORS FOR ESG INITIATIVES Source text for Eikon: Further company coverage:
DraftKings Named Sportsbook, Daily Fantasy Partner of Professional Fighters League
2021-04-20 09:30:33 AM ET (MT Newswires)
09:30 AM EDT, 04/20/2021 (MT Newswires) -- DraftKings (DKNG) has entered into a multi-year partnership to become the official sportsbook and daily fantasy partner of the Professional Fighters League, the PFL said Tuesday.
The collaboration will allow fans to wager on PFL fights via DraftKings, pending regulatory approvals, with the help of the league's SmartCage fight data and analytics technology. Live odds will also be integrated into each event broadcast across ESPN networks and platforms and presented by DraftKings.
PFL and DraftKings will also collaborate on exclusive, themed content across their social and digital platforms.
BRIEF-Draftkings Named First Official Sportsbook And Daily Fantasy Partner Of Professional Fighters League
2021-04-20 07:37:39 AM ET (Reuters)
April 20 (Reuters) - Draftkings Inc:
* DRAFTKINGS NAMED FIRST OFFICIAL SPORTSBOOK AND DAILY FANTASY PARTNER OF PROFESSIONAL FIGHTERS LEAGUE Source text for Eikon: Further company coverage:
VASCEPA(R) (Icosapent Ethyl) Reported to Impact Vulnerable Coronary Plaque Features in New Analyses of EVAPORATE Study Presented as Late-Breaking Science at ESC Preventive Cardiology 2021
2021-04-17 09:50:00 AM ET (GlobeNewswire)
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA(R) (icosapent ethyl) on top of statin therapy
Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months
Amarin Corporation plc (NASDAQ:AMRN) today announced that further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial were presented as Late-Breaking Science at European Society of Cardiology (ESC) Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology, on April 17, 2021, 3:50 PM CEST (Central European Summer Time) by Andrew Buckler, Founder and CTO of Elucid. As previously reported and published in the European Heart Journal, VASCEPA(R) (icosapent ethyl) demonstrated significant, 17% regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months. The Effect of Icosapent Ethyl on Changes in Coronary Plaque Morphology: EVAPORATE analyses presented at ESC Preventive Cardiology 2021 demonstrated that with administration of 4 g/day of VASCEPA on top of statin t herapy, there was an observed change in plaque stability occurring at 9 months and sustained through 18 months.
"The EVAPORATE plaque morphology study provides valuable insight into how we can utilize scientific imaging to examine the mechanisms at work that may contribute to observed clinical trial results," commented Matthew Budoff, M.D., Director of Cardiovascular CT at The Lundquist Institute and Professor of Medicine at the David Geffen School of Medicine at UCLA, the study sponsor. "The results suggest consistent benefits of icosapent ethyl on clinical cardiovascular outcomes as observed in the REDUCE-IT(R) cardiovascular outcomes study, and on plaque progression and plaque vulnerability as observed in EVAPORATE."
Of the 80 patients that were enrolled in the randomized, double-blind, placebo-controlled EVAPORATE trial, 55 patients had images that were able to be utilized for the histology-validated software. The EVAPORATE plaque morphology study used ElucidVivo (Elucid, Boston, MA), the first FDA-cleared analysis for specific tissue characterization using histopathologic correlates to assess plaque morphology characteristics, including Lipid Rich Necrotic Core (LRNC), fibrous cap thickness, and intraplaque hemorrhage (IPH). Whereas with placebo LRNC increased and cap thickness decreased, both indicative of moving to a less stable phenotype, with icosapent ethyl there was a measured LRNC decrease and cap thickness increase, indicative of moving to a more stable phenotype.
"Coronary plaque stabilization is an important finding with VASCEPA and may explain, in part, the substantial cardiovascular benefit seen in REDUCE-IT," said Craig Granowitz, M.D., Ph.D., Amarin's senior vice president and chief medical officer. "The EVAPORATE plaque morphology study results provide additional insight into one of the likely multifactorial effects of VASCEPA, which effects collectively have been shown or observed to lower residual cardiovascular risk."
The primary limitation of this single coronary plaque study as identified by its investigators is its small sample size. More study is needed to more fully understand the effects of VASCEPA on coronary plaque to determine the relationship, if any, of such plaque effects on cardiovascular risk reduction.
More information on ESC Preventive Cardiology 2021 can be found here.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
DraftKings' New Role as NFL Partner to Boost Consumer Adoption of Sports Betting, Oppenheimer Says
2021-04-16 10:40:56 AM ET (MT Newswires)
DraftKings' (DKNG) deal to be an official sports betting partner of the National Football League is expected to accelerate the legalization, as well as boost consumer adoption of sports betting, Oppenheimer said Thursday.
In a note to clients, Oppenheimer analysts said the partnership would also benefit in-game wagering, as the NFL would work more closely with its media partners to reduce latency.
DraftKings made the announcement on Thursday, adding that it will continue to be NFL's official daily fantasy partner. The deal has a three-year initial term, with two one-year options for NFL, according to the note.
With the move, NFL likely will change its policy and allow gambling commercials during its broadcasts, the analysts said.
Oppenheimer had an outperform rating on the stock.
DraftKings Named an Official Sports Betting Partner of the National Football League
2021-04-15 04:15:05 PM ET (GlobeNewswire)
DraftKings Inc. (Nasdaq: DKNG) and the National Football League (NFL or the League) announced today that DraftKings will become an Official Sports Betting Partner of the League and extend its current relationship as the exclusive Official Daily Fantasy Partner.
"The way fans consume sports years from now will look drastically different, and it will be due in part to forward-thinking collaborations like our expanded relationship with the NFL today as an Official Sports Betting Partner and the exclusive Daily Fantasy Sports Partner," said Jason Robins, CEO, chairman and co-founder, DraftKings. "We share the same vision as the NFL on fan engagement and believe this agreement will lead to new innovations that will ultimately enhance both the product on the field and on the screen."
As an Official Sports Betting Partner of the NFL, DraftKings will have the right to integrate relevant sports betting content directly into NFL Media properties including NFL.com and the NFL App. As part of the agreement, DraftKings will utilize the NFL's official League data feed. DraftKings will also be able to enhance their fan experience with NFL highlights, footage and Next Gen States content.
"We're thrilled to renew our relationship with DraftKings as the NFL's exclusive Daily Fantasy Sports Partner and expand it by adding them as an Official Sports Betting Partner," said Renie Anderson, Chief Revenue Officer and Executive Vice President of NFL Partnerships. "For several years DraftKings has helped find new and different ways to engage NFL fans and we expect that to increase with the evolution of legalized sports betting."
In addition to becoming an Official Sports Betting Partner of the NFL, DraftKings will renew its exclusive relationship as the Official Daily Fantasy Partner of the NFL, which provides DraftKings with exclusive rights to NFL marks to promote daily fantasy sports contests. DraftKings will continue to collaborate with the League on a variety of content and product offerings that fans can engage with on the DraftKings Sportsbook and Daily Fantasy Sports apps. The deal also includes integrations across NFL Media properties including a continued prominent presence within the NFL RedZone channel.
DraftKings is a Platinum Member of the National Council on Problem Gaming and is committed to industry-leading responsible gaming practices and providing its customers with the resources and services they need to play responsibly. In support of the NFL's commitment to protect the integrity of the game and its fans, DraftKings will adhere to the NFL's core integrity policies and will collaborate with the NFL on intelligence sharing, advocacy efforts and responsible gaming education.
About DraftKings
DraftKings Inc. is a digital sports entertainment and gaming company created to fuel the competitive spirit of sports fans with products that range across daily fantasy, regulated gaming and digital media. Headquartered in Boston, and launched in 2012 by Jason Robins, Matt Kalish and Paul Liberman, DraftKings is the only U.S.-based vertically integrated sports betting operator. DraftKings is a multi-channel provider of sports betting and gaming technologies, powering sports and gaming entertainment for 50+ operators in 17 countries. DraftKings' Sportsbook is live with mobile and/or retail betting operations in the United States pursuant to regulations in Colorado, Illinois, Indiana, Iowa, Michigan, Mississippi, New Hampshire, New Jersey, New York, Oregon, Pennsylvania, Tennessee, Virginia and West Virginia. DraftKings' daily fantasy sports product is available in 8 countries internationally with 15 distinct sports categories. DraftKings is the official daily fantasy partner of the NFL, MLB, NASCAR, PGA TOUR and UFC as well as an authorized gaming operator of the NBA and MLB, an official betting operator of the PGA TOUR and the official betting operator of UFC. DraftKings also owns Vegas Sports Information Network, Inc. (VSiN), a multi-platform broadcast and content company.
DraftKings, PGA TOUR Expand Relationship for Sports Betting in Arizona, Plan Retail Sportsbook at Golf Venue
2021-04-14 07:53:37 AM ET (MT Newswires)
07:53 AM EDT, 04/14/2021 (MT Newswires) -- DraftKings (DKNG) and the PGA TOUR said Wednesday they will expand their existing commercial partnership to provide DraftKings market access to retail and mobile sports betting in Arizona.
This expanded partnership follows the Arizona Legislature's passage of HB 2772, which would authorize fantasy sports and sports betting in the state pending approval from Governor Doug Ducey.
The companies also plan to operate a retail sportsbook at a golf complex TPC Scottsdale.
DraftKings will also become the exclusive sports betting partner of the Waste Management Phoenix Open held annually at TPC Scottsdale, according to a statement.
DraftKings to Release First Quarter 2021 Results May 7
2021-04-12 07:30:06 AM ET (GlobeNewswire)
DraftKings Inc. (Nasdaq: DKNG) (the "Company", "DraftKings") today announced that it will release its first quarter 2021 results prior to 8:30AM EDT on May 7, 2021.
At 8:30AM EDT on the same day, DraftKings will host a conference call to discuss the results.
The Company's earnings press release and related materials will be available at investors.draftkings.com. To listen to the audio webcast and live Q&A, please visit DraftKings' investor relations website at investors.draftkings.com. The audio webcast and accompanying presentation will be available on the Company's investor relations website until 11:59PM EDT on June 14, 2021.
About DraftKings
DraftKings Inc. is a digital sports entertainment and gaming company created to fuel the competitive spirit of sports fans with products that range across daily fantasy, regulated gaming and digital media. Headquartered in Boston, and launched in 2012 by Jason Robins, Matt Kalish and Paul Liberman, DraftKings is the only U.S.-based vertically integrated sports betting operator. DraftKings is a multi-channel provider of sports betting and gaming technologies, powering sports and gaming entertainment for 50+ operators in 17 countries. DraftKings' Sportsbook is live with mobile and/or retail betting operations in the United States pursuant to regulations in Colorado, Illinois, Indiana, Iowa, Michigan, Mississippi, New Hampshire, New Jersey, New York, Oregon, Pennsylvania, Tennessee, Virginia and West Virginia. DraftKings' daily fantasy sports product is available in 8 countries internationally with 15 distinct sports categories. DraftKings owns Vegas Sports Information Network, I nc. (VSiN), a multi-platform broadcast and content company. DraftKings is the official daily fantasy partner of the NFL, MLB, NASCAR, PGA TOUR and UFC as well as an authorized gaming operator of the NBA and MLB, an official betting operator of the PGA TOUR and the official betting operator of UFC.
The price won’t go above 0.42 CDN, in doing so, buyers will be losing out on the conversion.
I sold out all of my shares at 0.41 CDN. If you do the math on 1 FIRE share yields 0.01165872 Canopy shares plus 0.0001 in cash, basically price shouldn’t go higher than 0.425 CDN (with Canopy’s current price).
Under the terms of deal, Supreme Cannabis shareholders will receive 0.01165872 of a Canopy common share and C$0.0001 in cash in exchange for each Supreme Cannabis share held.
Nice and steady price uptrend, creating new support bases along the way.
Amarin Commences Commercial Initiatives for VAZKEPA in European Union Following Recent Regulatory Approval for Cardiovascular Risk Reduction Indication
2021-04-06 06:05:00 AM ET (GlobeNewswire)
Reimbursement dossiers for first 10 countries to be filed in coming months
150 people hired and on-track to be deployed by mid-Q2 2021 supplemented by digital outreach and medical education programs with initial top priority on Germany
VAZKEPA commercial launch in Germany planned for Q3 2021
Amarin Corporation plc (NASDAQ: AMRN) today provided updates regarding its plans for the commercial launch of VAZKEPA (icosapent ethyl) in Europe following the March 30, 2021 announcement of receipt of market authorization from the European Commission (EC). VAZKEPA is the first EC-approved product to be marketed and sold for cardiovascular risk reduction in high-risk, statin-treated adult patients who have elevated triglycerides (greater-than or equal to150 mg/dL) and other risk characteristics as studied in REDUCE-IT(R).
Following this approval, Amarin commenced training sales representatives in Germany to advance pre-launch disease and brand awareness initiatives in preparation for the planned commercial launch of VAZKEPA in Germany before the end of Q3 2021. The company expects to have approximately 150 sales representatives deployed for pre-launch product and disease state awareness programs by mid-Q2 2021.
"We have hired talented and experienced pharmaceutical sales and marketing professionals for our European commercial team and are activating steps to increase product and market need awareness, while advancing our market access negotiations," said Karim Mikhail, senior vice president, commercial head Europe of Amarin. "We are taking a thoughtful and proactive approach to leveraging the vast global experience of our team, while incorporating the learnings from other product launches made during the COVID-19 era. We are highly motivated to effectively launch VAZKEPA in Europe as it offers an exciting opportunity to help patients at risk of cardiovascular events. VAZKEPA is a safe and effective new product that benefits from more than a decade of worldwide clinical development and testing that support its use to significantly reduce cardiovascular events."
Use of icosapent ethyl is now recommended by 15 medical societies for cardiovascular risk reduction reflecting that the data supporting the effectiveness of VAZKEPA is robust, the medical need is high and key opinion leaders in these medical societies agree this important new drug should be used to improve patient care. As VAZKEPA was just recently authorized in Europe as a new drug (new active substance), and there is no other product approved in Europe for VAZKEPA's indication, current awareness of VAZKEPA in Europe among healthcare professionals at-large is relatively low.
Amarin believes that increasing awareness of VAZKEPA in Germany and illuminating the patient population that can benefit from this new drug are important to VAZKEPA's early launch success. Prior to VAZKEPA's recent approval, as is typical for any new drug, branded market education regarding VAZKEPA was prohibited in Europe. Consequently, immediately following VAZKEPA's approval in the European Union the company has initiated its educational and promotional plans to underscore the significant residual cardiovascular risk for the patient population indicated for VAZKEPA and to introduce to healthcare professionals the value VAZKEPA has demonstrated in lowering such risk.
Starting in the second quarter 2021, outreach by Amarin's field force in Germany will be supplemented by various forms of market education, including digital outreach and omnichannel engagement for key stakeholders. Amarin's planned educational initiatives are intended to increase awareness among cardiologists, diabetologists, and general practitioners. In addition, based on the differentiated safety and efficacy profile of this unique drug for its approved label and the growing global data in support of its pharmacoeconomic benefits, our planned educational efforts will also be aimed at regional payers.
As is typical of drug launches in Europe, following approval and prior to launch, market access (reimbursement) needs to be secured on a country-by-country basis and product awareness of VAZKEPA needs to increase in each country. In seeking market access, the company expects to file dossiers in ten (10) European countries in the coming months, including the largest countries of Europe. Each of these dossiers have already undergone months of preparation and include the data demonstrating the uniqueness of VAZKEPA from a scientific perspective, various country-specific demographic data sets to define the eligible patient population based on the label, and finally proposed pricing. Amarin is seeking pricing that it believes is well justified based on the demonstrated effectiveness of VAZKEPA and the high cost to society of heart attacks, strokes and other cardiovascular events that VAZKEPA can help avoid while also reducing pain and suffering for at-risk patients and their famili es. After the first wave of 10 country submissions in Europe, Amarin intends to pursue a second wave of European reimbursement dossiers in its efforts to bring VAZKEPA to all patients who can benefit from it.
Amarin anticipates direct access to healthcare professionals and at-risk patients will remain constrained while COVID-19 persists. Learning from the experience of other drugs launched during the COVID-19 pandemic, part of the planned multi-faceted educational programs in Europe will include increased awareness of the unique effects of VAZKEPA. For example, key elements of the planned education initiatives are expected to focus on increasing the scientific awareness of the importance of measuring and using triglyceride (TG) levels as an identifier of cardiovascular risk, noting that VAZKEPA's cardiovascular risk reduction effects extend beyond TG lowering and are believed to be multifactorial, including anti-inflammatory and antiplatelet effects. While many people are speculating that the impact of COVID-19 will gradually abate around the planned commercial launch of VAZKEPA in Germany in Q3 2021, digital outreach, and other forms of educating healthcare professionals will be e mphasized to support the work of the sales professionals being deployed. In order to advance pre-launch market awareness of VAZKEPA, to allow time for the impact of COVID-19 to recede and to avoid the challenges of launching prior to the summer holiday period when access to healthcare professionals can be more difficult, it is likely that the launch in Germany will be the latter half of Q3. Launch timing will be further refined after feedback is received from the company's early branded awareness and education initiatives.
Amarin is giving initial priority to launching VAZKEPA in Germany while making plans for commercialization in countries throughout Europe. Staffing in other European countries, and launch timing in these other countries, will depend on progress in gaining market access on a country-by-country basis.
Previously Amarin had provided guidance that its European staffing at the end of 2021 would be approximately 200 people. Based on the company's current plans and expectations, Amarin now expects to grow its staffing in Europe to approximately 300 people by the end of 2021, with further increases planned as market access is expanded in various countries. This increase in expected staffing reflects the breadth of the EC-approved label for VAZKEPA, positive initial feedback Amarin is receiving from European scientific leaders, and optimism that the impact of COVID-19 will recede during the second half of 2021.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.